The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target […]

Join industry leaders like Eli Lilly, Merck, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12, 2024 – Philadelphia, PA). This is your perfect moment to […]

Join 100+ leading PAT scientists, engineers, process development, CMC, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies, engage in dynamic roundtables and deep dive into […]

Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies: […]

The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets, never-before-seen pre-clinical and clinical data, and demonstrating key routes to commercial success for […]

RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and […]

The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving […]

Fresh from the reapproval of Roche/Genentech’s Susvimo, positive readouts for sustained release implants, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina, matching the right delivery route to the […]

Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling […]

The kinase drug discovery field is at a pivotal moment, with recent breakthroughs from industry leaders such as Biogen, A-Alpha Bio, and Proxygen paving the way for exciting new approaches in targeting kinases, particularly […]

Significant breakthroughs in CNS biology, coupled with innovative neuroscience technologies and a more supportive regulatory landscape, have fueled increased investment and pharmaceutical interest in the CNS. With AbbVie, BMS, and […]

In recent industry news, AAV gene therapies are gaining momentum, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy […]

Advancing Curative Therapies for Autoimmune Diseases  Building on the success of last year’s meeting, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. […]

Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with […]

4th mRNA Analytical Development & Quality Control Summit | February 25-27, 2025 Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running. […]

The radiopharmaceutical race is on and pharma leaders such as AstraZenca, BMS , Eli Lilly, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical […]

2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data, expansion into autoimmune disease, and combination […]

Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval, the field has seen a surge […]

In the current cell therapy landscape, where funding is tight and clinical development a priority, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency […]

The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable, traceable, and resilient global supply chains to support the growing […]

Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. […]

With Merck's acquisition of EyeBio for $1.3 Billion, Roche's Vabysmo launch success and multiple other phase II and III trials in DME, DR, RVO, and Wet AMD, there is plenty […]

The field of conjugatable drugs is advancing at a rapid pace, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals, which paves the […]

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum […]

In today’s complex drug development landscape, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through […]

As the biopharma industry evolves with rapid advancements in drug development, manufacturing, and research, EHS leaders are tasked with safeguarding employee health, maintaining a culture of safety, and addressing environmental […]

Over the past year, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca, and Parvus and AbbVie, creating a surge of innovation and spotlighting Treg […]

The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. With the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033, […]

With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use, nasal delivery is opening a […]

The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025, bringing together over 80 experts in peptide computational science, medicinal chemistry, and formulation to discuss the latest advancements […]